Inspyr Therapeutics (NSPX) has turned into a monster runner and a massive win for our subscribers that got our alert last Friday. Most of our subscribers have averaged in around $.01 and saw a quick three day run to $.07 on Tuesday. While some have booked profits and taken some money off the table, there’s still a lot more room for NSPX to run before the New Year.
As you can see from the chart above, shares of NSPX were trading at $1 not too long ago. With the news last week that Inspyr Therapeutics has regained control of its key cancer-treating technology, we could see $1 yet again, especially with NSPX’s low float and the MMs short.
Inspyr Therapeutics (NSPX)
First up, here’s a little background info for those not familiar with NSPX. Inspyr Therapeutics is now focused on the development of immune-oncology precision therapies that utilize its proprietary technology targeting the delivery of adenosine receptor antagonists as treatments for cancer.
Inspyr intellectual property (IP) was developed over 15 years at Johns Hopkins University and the University of Copenhagen with over $15 million in scientific grants from the National Cancer Institute, the U.S. Department of Defense, and the U.S. National Institutes of Health, among others. Inspyr has strategically expanded its portfolio to include 15 issued U.S. patents and more than 40 pending applications worldwide, focused on the U.S., Europe, and the Asia Pacific.
NSPX has reacquired a novel immuno-oncology delivery technology targeting adenosine receptor antagonists for the treatment of cancer. The technology was previously acquired by Inspyr and then licensed to Ridgeway Therapeutics, Inc. in exchange for (i) 65,000,000 shares of Common Stock and (ii) 8,000 shares of Series F Convertible Preferred Stock.
Inspyr has reacquired all rights previously licenses, as well as improvements thereto made by Ridgeway, and will assume all further preclinical and clinical development relating to RT-AR001 and all other proprietary assets. Preclinical data demonstrated delayed tumor growth, reduces metastases, and anti-tumor immune response.
Adenosine Receptor Modulators
NSPX is focusing on a pipeline of small molecule adenosine receptor modulators. The adenosine receptor modulators include A 2B antagonists, dual A 2A /A 2B antagonists, and A 2A agonists that have broad development applicability including indications within immuno-oncology and inflammation.
Adenosine is implicated in immunosuppression in the tumor microenvironment. Adenosine receptor antagonists may boost the host immune response against the tumor as a single-agent and in combination with other existing immuno-oncology agents leading to enhanced tumor killing and inhibition of metastasis.
Adenosine also has anti-inflammatory properties in the acute and chronic setting. Adenosine receptor agonists may promote a decreased inflammatory response and can potentially treat a broad range of inflammatory and autoimmune based diseases and conditions (e.g., rheumatoid arthritis, joint injury, Crohn’s disease, psoriasis) as well as improve wound healing and decrease pain.
NSPX Game Plan
During February 2018, due to a lack of capital, NSPX curtailed substantially all business operations. By reacquiring its technology from Ridgeway, Inspyr Therapeutics plans to:
- further characterization, in conjunction with Ridgeway Therapeutics, of anti-cancer activity of the current pipeline of A2B antagonists and dual A2A/A2B antagonists leading to the selection of a clinical candidate for an Investigative New Drug or IND enabling studies
- further characterization of the current pipeline of A2A agonists leading to the selection of a clinical candidate for an Investigative New Drug or IND enabling studies
- licensing and/or partnering the A2B antagonists, dual A2A/A2B antagonists, and/or A2A agonists for further development
- through its newly acquired adenosine receptor chemistry technology platform, continue to produce next-generation adenosine receptor modulators
- pursue licensing and/or partnering of mipsagargin
- conduct a clinical study of mipsagargin in patients with advanced HCC
- explore collaborations utilizing mipsagargin in new, non-clinical solid tumor models with leading researchers in the oncology field.
Mipsagargin is a pro-drug that has completed a phase 2 clinical trial for the treatment of liver cancer, and the ARM preclinical programs consisting of A2A, A2B, and dual A2A/A2B receptor antagonists for the treatment of cancer and A2A agonists for the treatment of inflammatory and other serious diseases.
The Bullish Case For NSPX
- The data from nonclinical studies appear promising and demonstrated delayed tumor growth, reduces metastases, and anti-tumor immune response.
- Global cancer/tumor profiling market size is projected to reach USD 13.9 billion by 2025 from USD 8.3 billion in 2020, at a CAGR of 10.9 %.
- NSPX is actively seeking licensing opportunities and/or partners to further develop its A2B and dual A2A/A2B receptor antagonists.
- NSPX is working toward IND enabling studies and support ongoing licensing/partnership activities.
- Since its inception, NSPX has raised $37.5 million to develop its A2B and dual A2A/A2B receptor antagonists. There is substantial value in its technology. It also proves that the company can raise money.
- NSPX owns a patent portfolio that includes 15 issued U.S. patents and more than 40 pending applications worldwide, focused on the U.S., Europe, and the Asia Pacific.
Obviously, something is brewing behind the scenes with NSPX and Ridgeway. This deal is not a coincidence. We believe that NSPX has identified funding to advance its current pipeline. When you consider that this is a company with 15 U.S. patents and 40 pending worldwide, the potential is enormous for a penny stock.
The deal between Ridgeway and NSPX makes a lot of sense when you think about it. Ridgeway is a private company and NSPX is publicly traded. By taking shares in NSPX, Ridgeway benefits from the stock appreciation. Again, the smart money is making some serious moves here.
Finally, congratulations to all that got in at $.01 or under. Taking some money off the table is a prudent move, but there’s massive potential in NSPX if the company can execute. We will continue our coverage for our Insider Financial subscribers.
As always, good luck to all (except the shorts)!
WHEN INSIDER FINANCIAL HAS A STOCK TIP, IT CAN PAY TO LISTEN. AFTER ALL, OUR FREE NEWSLETTER HAS FOUND MANY TRIPLE-DIGIT WINNERS FOR OUR SUBSCRIBERS. WE SPECIALIZE IN FINDING MOMENTUM BEFORE IT HAPPENS!
Disclosure: We have no position in OTCMKTS:NSPX or any of the securities mentioned. We wrote this article ourselves and it expresses our own opinions. We are not receiving compensation for it. We have no business relationship with any company whose stock is mentioned in this article. Insider Financial is not an investment advisor and does not provide investment advice. Always do your own research and make your own investment decisions. This article is not a solicitation or recommendation to buy, sell, or hold securities. This article is meant for informational and educational purposes only and does not provide investment advice.